Kylo 04
Alternative Names: Kylo-04Latest Information Update: 16 Aug 2024
At a glance
- Originator Kylonova (Xiamen) Biopharma
- Class Antivirals; Small interfering RNA
- Mechanism of Action Hepatitis B e antigen inhibitors; Hepatitis B surface antigen inhibitors; RNA interference; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 29 Jul 2024 Kylonova (Xiamen) Biopharma has patent protection for Nano-Lipid Particle (NPDP), Multi-Valent Import platform (MVIP) and Lipid-Coupling Delivery platform (LCDP) (Kylonova (Xiamen) Biopharma pipeline, July 2024)
- 29 Jul 2024 Preclinical trials in Hepatitis B in China (Parenteral) prior to July 2024 (Kylonova Biopharma pipeline, July 2024)